Michel Vounatsos and Carl Berg come from very different corners of the business world. Vounatsos built his reputation through global pharmaceuticals and biotechnology, including his tenure as Biogen CEO, while Berg became known for Silicon Valley real estate, venture capital, and technology investments. Their education, careers, wealth estimates, and public profiles reflect those different paths. The table below brings the key biographical and professional details together in one detailed comparison.
Michel Vounatsos and Carl Berg Quick Bio
| Profile Detail | Michel Vounatsos | Carl Berg |
|---|---|---|
| Full Name | Michel Vounatsos | Carl Edwin Berg |
| Date of Birth | Estimated 1961–1962; exact date is not publicly documented | 1938; exact month and day are not publicly documented |
| Nickname | Unverified; no widely documented nickname | Unverified; no widely documented nickname |
| Birthplace | France; specific city not clearly documented | New Mexico, USA |
| Age | About 64 years old in 2026; public records have listed him at 59 in 2021 | About 88 years old in 2026; Forbes currently lists 89, while other databases list 88 |
| Nationality | French; he has also been publicly reported as having Greek citizenship and Greek family heritage | American |
| Profession | Pharmaceutical Executive, Biotechnology Executive, Business Leader and Corporate Director | Real-Estate Investor, Developer, Businessman and Venture Capitalist |
| Famous For | Former CEO of Biogen (2017–2022) and senior leadership at Merck | Silicon Valley real estate, Mission West Properties and technology investments |
| Net Worth | Estimated around $4 million according to MarketScreener’s August 2026 estimate; this is not an official personal net-worth disclosure | Historical estimate of about $1.1 billion by Forbes in March 2013; current wealth is not officially verified |
| Source of Wealth | Pharmaceutical executive compensation, investments and corporate board holdings | Real estate, venture capital and technology investments |
| Education | C.S.C.T. Certificate in Medicine, Université Victor Segalen, Bordeaux II; MBA, HEC School of Management, Paris | Bachelor’s degree, University of New Mexico |
| Parents | Unverified / not publicly documented | Father reportedly died in a construction-site accident; mother’s name is not publicly documented |
| Siblings | Unverified / not publicly documented | One brother, Clyde Berg, who was also involved in real estate |
| Family Background | Greek family heritage has been publicly reported | Born and raised in New Mexico; brother Clyde also became a real-estate developer |
| Marital Status | Unverified / not publicly documented | Married |
| Wife / Partner | Unverified / not publicly documented | Wife’s name is not widely documented in major business biographies |
| Children | Unverified / not publicly documented | One daughter |
| Height | Estimated around 5 ft 10 in (178 cm) — unofficial | Estimated around 5 ft 10 in (178 cm) — unofficial |
| Weight | Estimated around 78–82 kg — unofficial | Estimated around 78–82 kg — unofficial |
| Hair Color | Gray/white — appearance-based estimate | Gray/white — appearance-based estimate |
| Eye Color | Estimated brown; not officially documented | Unverified; no reliable published measurement found |
| Hobbies | Unverified; specific hobbies are not consistently documented | Unverified; specific hobbies are not consistently documented |
| No clearly verified official personal account identified | No clearly verified official personal account identified | |
| Career Field | Pharmaceuticals, biotechnology, healthcare and life sciences | Real estate, venture capital and technology |
| Early Career | Management positions at Ciba-Geigy, followed by a long career at Merck | Loan officer in Texas, followed by mortgage and real-estate work in California |
| Merck Career | About 20 years at Merck, with leadership roles in Europe, China and the United States | Not applicable |
| Biogen Career | Executive VP and Chief Commercial Officer (2016–2017); CEO and Director (2017–2022) | Not applicable |
| Biogen CEO Period | 2017–2022 | Not applicable |
| Mission West Properties | Not applicable | Acquired Mission West Properties in 1997 and led it as Chairman, President and CEO |
| Mission West Sale | Not applicable | Sold to Divco West in 2012 in a transaction valued at about $1.3 billion |
| Technology Investments | Focused primarily on pharmaceutical and biotechnology businesses | Invested in more than 100 technology startups |
| Venture Capital | Corporate and healthcare investment experience | Founded West Coast Venture Capital in 1998 |
| Major Business Interests | Biotechnology, pharmaceuticals, healthcare and corporate boards | Commercial real estate, technology companies, venture capital and private investments |
| Current Board Role | Director at Zai Lab and Revvity | Chairman at Quantum3D and involvement with several private companies and investment ventures |
| Zai Lab | Board Director since 2023 | Not applicable |
| Revvity | Board Director since 2020 | Not applicable |
| Berg & Berg | Not applicable | Associated with Berg & Berg Enterprises and Berg & Berg Developers |
| Berg LLC / Berg Health | Not applicable | Associated with a biotechnology venture using data-driven approaches to drug discovery |
| Known Leadership Strength | Global pharmaceutical management, commercial strategy and international markets | Real-estate development, technology investment and venture capital |
| Public Profile | Low-profile pharmaceutical and biotechnology executive | Low-profile Silicon Valley businessman and investor |
| Residence | Not publicly confirmed | Atherton, California |
| Estimated Career Length | More than 30 years in pharmaceuticals and biotechnology | Several decades in real estate, technology and investment |
| Notable Achievement | Led Biogen as CEO from 2017 to 2022 after two decades at Merck | Built a major Silicon Valley real-estate and investment career and completed the $1.3 billion Mission West transaction |
| Overall Business Focus | Healthcare and life sciences | Real estate and technology |
Michel Vounatsos and Carl Berg Images
